meta
|
evidence
oncology
Living systematic review and meta-analysis
malignant mesothelioma (mMS) - 2nd line (L2)
2
multiple myeloma
immune chekpoint inhibitors
anti-CTLA-4
tremelimumab
anti-PD-(L)1
nivolumab based treatment
nivolumab alone
versus all
vs non active control
vs placebo
All patients
PD-L1 < 1%
PD-L1 > 1%
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS)
progression or deaths (PFS)
AE (grade 3-4)
AE leading to death (grade 5)
SAE (any grade)
deaths (OS)
malignant mesothelioma (mMS) - 2nd line (L2)
malignant mesothelioma (mMS) - 2nd line (L2)
versus placebo
nivolumab alone vs. placebo
1
certainty unassessable
-26%
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open